

82-34639

**AGENIX LIMITED**

11 Durbell Street P.O. Box 391  
Acacia Ridge QLD 4110  
Australia  
Tel : +61 (0)7 3370 6396  
Fax : +61 (0)7 3370 6370  
Website : www.agenix.net



~~SEC#82-5258~~



18 August 2003

US Securities and Exchange Commission  
Attention: Filing Desk  
450 Fifth Street NW  
WASHINGTON DC 20549  
USA

**PROCESSED**

SEP 04 2003

THOMSON  
FINANCIAL

**SUPPL**


Dear Sir

**Re: Submission Under Rule 12g3-2(b) - Agenix Limited**

We refer to the attached announcement that was made to the Australian Stock Exchange. We are providing a copy of this announcement by virtue of our requirements under Rule 12g3-2(b).

Yours sincerely

Neil Leggett  
Company Secretary



## COMPANY ANNOUNCEMENT

### Agenix Secures \$20 Million Loan Facility from Commonwealth Bank

Thursday 14 August 2003

Agenix Limited today announced that it has secured a \$20 Million bank bill facility from the Commonwealth Bank to underpin its growth objectives.

"The strength of our balance sheet and underlying cash flows has enabled us to exploit our debt raising capacity," said Agenix Chief Financial Officer, Neil Leggett. "Whilst we had \$9.5 million in cash at 30 June 2003, the establishment of the Commonwealth Bank facility enables the company to more accurately assess its capacity to fund growth opportunities as they arise."

Agenix Managing Director, Don Home said: "This facility enables us to respond quickly to opportunities such as bolt-on acquisitions that will both improve Agenix's cash flow and expand our product range. The facility also provides us with the ability to fund expected strong growth in our core businesses, particularly in animal health diagnostics."

"We are confident that we will be able to fund the development of ThromboView® through to the point of commercialisation without the need to raise any additional capital. The Commonwealth Bank has provided an excellent service in structuring a facility offer which enables us to pursue other growth opportunities as well."

**For more information contact:**

Mr Don Home  
Managing Director  
Agenix Limited  
Ph: 61 7 3370 6300

**Agenix Limited [ASX:AGX, NASDAQ: AGXLY]** is a listed company based in Brisbane, Australia, and is part of the Standard & Poor's/ASX 300 index. It manufactures, distributes and markets human and veterinary diagnostic test kits, over-the-counter pharmaceuticals and infant care products via its wholly-owned subsidiaries AGEN Biomedical and Milton Pharmaceuticals. Agenix focuses on developing a horizontally-integrated product portfolio to service the needs of the acute phase thrombosis market. Agenix's lead

candidate is its high-technology ThromboView® blood clot-imaging project, which is currently undergoing human trials. ThromboView® uses radiolabelled antibodies to locate blood clots in the body. It could revolutionise the US \$3 billion global clot diagnostic imaging market. ThromboView® is being developed with the assistance of the Federal Government through its START scheme. Agenix employs 200 staff and sells its products to more than 50 countries. ThromboView® is a registered trademark of AGEN Biomedical.